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Abstract 
Exosomes are released by normal and tumour cells, including those involved in breast cancer, 
and provide a means of intercellular communications. Exosomes with diameters ranging 
between 30-150 nm are involved in transferring biological information, via various lipids, 
proteins, different forms of RNAs, and DNA from one cell to another, and this can result in 
reprogramming of recipient cell functions. These vesicles are present in all body fluids, e.g., 
blood plasma/serum, semen, saliva, cerebrospinal fluid, breast milk, and urine. It has been 
recently reported that these particles are involved in the development and progression of 
different tumor types, including breast cancer. Furthermore, it has been suggested that 
exosomes have the potential to be used as drug transporters,  or as biomarkers. This review 
highlights the potential roles of exosomes in normal and breast cancer cells and their potential 
applications as biomarkers with special focus on their potential applications in treatment of 
breast cancer. 
 
Key words: breast cancer, exosomes, non-invasive biomarker, therapeutic target 
  
3 
 
Introduction 
Breast cancer is the most common cancer among women and is the most common cause of 
cancer-related mortality in women globally [Wu et al. 2016]. Breast cancer is pathologically 
heterogeneous; they may be aggressive tumors with a very poor prognosis, or slow growing 
indolent tumors with a good prognosis [Tao et al. 2015]. The incidence rates of breast cancer 
are lower in less developed countries than in more developed countries, whereas the prevalence 
and related death rates are increasing in both groups of countries [Tamimi 2017]. Based on 
GLOBOCAN statics in 2012, 1.7 million breast cancer cases were diagnosed among women, 
and 0.5 million death from this disease have been recorded globally in 2012 [Wu et al. 2016; 
Toriola and Colditz 2013]. The lack of understanding of the molecular mechanisms of breast 
cancer pathogenesis has led to poor clinical outcomes [Kruger et al. 2014; Harris et al. 2015]. 
Exosomes were first described in relation to their role in excess transferrin receptor exocytosis 
in sheep cells in vitro [Pan et al. 1985]. These small vesicles (30-100 nm) have been proposed 
as a means of intercellular communication, and that are now known to be released from various 
cell types, including dendritic cells, B cells, T cells, endothelial cells, stem cells and especially 
cancer cells [Yu, Zhang, and Li 2014; Soung et al. 2017]. Exosomes originate from the 
endosomal membrane compartment and contain a large variety of components such as RNAs 
and proteins [Inamdar, Nitiyanandan, and Rege 2017]. These latter proteins include membrane 
associated proteins, such as tetraspanin, CD63, CD81, CD82and CD9, and cytoplasmic 
proteins, such as Hsp 90 and Hsp 70, Protein Alix and TSG101. In addition, they include 
membrane transport and fusion proteins, such as RabGTPases and Annexins. They also contain 
major histocompatibility complex (MHC) class-I and class-II, FasL and adhesion molecules, 
metalloproteinases and tissue-specific proteins associated with tumorigenesis and 
metastasis [Mollaei, Safaralizadeh, and Pouladi 2017]. Exosomes may also contain mRNAs, 
MicroRNAs, and DNA fragments [Wang et al. 2016]. 
4 
 
As their name suggests, tumor-derived (TD) exosomes are vesicles, secreted from tumor 
cells [Kalluri 2016]. TD exosomes, may contain molecules, that reflect characteristics of the 
tumor cells from which they are derived; thus, exosomes may be used as biomarkers in the 
diagnosis of cancer [Roma-Rodrigues, Fernandes, and Baptista 2014; Dijkstra et al. 2014; 
Aushev et al. 2013]. There is some evidence that TD exosomes may be involved in constructing 
a microenvironment that supports the spread of a tumor, invasion, angiogenesis and pre-
metastatic niche development [Graner, Cumming, and Bigner 2007; Khan et al. 2014]. 
Moreover, TD exosomes have other emerging characteristics that include; restricting immune 
control and enhancing chemo-resistance by elimination of chemotherapeutic drugs, which may 
facilitate tumor growth and metastasis [Wang et al. 2016; Aushev et al. 2013].  
Consequently, TD-exosomes may be potential targets for targeted therapy, by their removal or 
modification [Khalyfa et al. 2016; Zhang and Grizzle 2014]. Because exosomes secrete 
important mediators, they have been proposed to act as regulators of cancer [Melo et al. 2014]. 
Exosomes promote cell migration, cancer progression and  metastasis by the secretion of 
growth factors, angiopoietin factors and cytokines from stromal cells, induce proliferation of 
endothelial cells, and promote angiogenesis in metastatic organs [McGarty 2013]. Exosomes 
show differential enrichment of proteins with signatures of both identity and abundance of 
cancer cells [Syn et al. 2017]. Hence, the search for cancer-cell-derived exosomes in a 
metastatic pattern may determine the mechanism of cancer. In addition, they may be novel 
biomarkers for the detection of early stage cancer and metastasis; which are new therapeutic 
strategies for cancer [Soung et al. 2017]. 
Extracellular vehicles (EVs) 
 There are three different mechanisms for EVs being secreted by cells. These are: multi 
vesicular endosomal cell compartment, cell budding, and apoptotic bodies. Exosomes are 
released from the multi vesicular endosomal cell compartment into the ECM (extracellular 
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matrix); it allows them to circulate via the body fluids. Exosomes are small membranous 
vesicles (30–100 nm), which are secreted from many types of cells; these vesicles are one 
means of intercellular communication and shuttling of intracellular contents (protein and 
RNA). Exosomes could therefore be a source of biomarkers that could be used in the diagnosis 
of a variety of diseases [Raposo and Stoorvogel 2013]. 
Function and Composition of exosomes (Biogenesis)  
Exosomes are formed during the late endosomic phase of cell development; double inward 
budding of the endosomal membrane initiates the formation of exosomes [Miller and 
Grunewald 2015]. Multi vesicular bodies produce exosomes through the invagination of their 
membrane and afterwards they fuse with the cell membrane, in order to secrete these 
exosomes[Miller and Grunewald 2015].  
Exosomes reflect the characteristics of the original cell type, and their contents are selectively 
loaded. However, the relative amounts of RNA and protein are different from the parent cell. 
The emergence of exosomes through this inward budding comprises a wide range of surface 
proteins and bears variety of lipids, nucleic acids such as miRNA’s and mRNA’s, and 
proteins [Vader, Breakefield, and Wood 2014]. The exosomes derived from MVB can 
influence a recipient cell by changing its phenotype and function [Jakobsen et al. 2015].  
Potential of EVs as biomarkers 
Studies on the potential use of exosomes as biomarkers, were started when it was found that 
they can transport their load through the circulation to distant cells around the body. Exosomes 
are found in the blood and urine. In addition, they contain potentially important biomarkers 
such as tumor-specific proteins [Ogorevc, Kralj-Iglic, and Veranic 2013; Théry et al. 2006], 
[Nazimek et al. 2015]. Tumor derived exosomes, may be involved in metastasis, invasion and 
the advancement of the cancer cell [Kahlert and Kalluri 2013]. On the other hand, exosomes 
enhance angiogenesis in hypoxia and facilitate the metastasis of cancer cells, by modulation of 
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hypoxia-inducible factors’ (HIF) family of transcription factors. Tumor-derived exosomes may 
prevent immune responses and allow the progression of cancer. They may also have an 
important role in the cancer cell resistance to chemotherapy. 
Exosomes are suggested to be potential biomarkers for cancer diagnosis and assessment of 
prognosis. They contain various proteins, peptides and tumor specific antigens, or have 
compounds on their surface that have the capability to target particular cells [Dorayappan et al. 
2016; Tran et al. 2015]. The concentration of exosomes in the blood of cancer patients is higher 
than for healthy subjects; and there is a positive association between malignant tumor growth 
and these increased numbers [Tang and Wong 2015]. There are also differences in protein and 
NA (nucleic acid) content in exosomes from patients with and without cancer, and can affect 
tumor growth by promoting endothelial angiogenic responses [Al-Nedawi et al. 2009]. 
There is evidence for a role of exosomes released by cancer cells, contributing to disease 
progression, tumorigenesis, angiogenesis, metastasis, chemo-resistance, pre-metastatic 
establishment, immune inhibition and ECM remodeling [Andaloussi et al. 2013]. Comparing 
the exosomes derived from the supernatant derived from cancer cell cultures, or from the serum 
of cancer patients, with those derived from non-cancerous individuals has shown a significant 
increase in exosomes in cancerous samples. There is an up-regulation of exosome secretion in 
cancer cells [Brinton et al. 2015]. TD exosomes have the ability to exchange material between 
cancer cells and are capable of communicating with various cell types in the periphery. Cancer 
cells also secrete exosomes that have the potential to reprogram their micro-environment; 
altering this to facilitate tumor growth and invasion of healthy tissues. The microenvironment 
consists of the extracellular matrix and stromal cells such as endothelial cells, fibroblasts and 
inflammatory immune cells, and tumor-associated vasculature [Joyce and Pollard 2009]. 
Studies have also demonstrated a role of adipose stromal cells (adipocytes), in the development 
of tumorigenic microenvironment, specifically in obesity-related cancers(38).  
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Cancer cells release exosomes that may affect fibroblasts, allowing them to organize a more 
favorable tumor microenvironment by eliciting the TGFβ/Smad pathway in target cells [Quail 
and Joyce 2013; Spill et al. 2016]. In some cases, the exosomal secretion of extracellular matrix 
metalloproteinase can promote fibroblast remodeling of the TME [Webber et al. 2010; 
Millimaggi et al. 2007]. In recent studies, TD exosomes have been found to be contributory 
factors to EMT/ epithelial to mesenchymal transition, causing TMEs to become more able to 
metastasize and more invasive (41). Oncogenic transmission leading to the process of EMT is 
likely to be mediated by exosomal cargo transfer which is associated with tumor-driving 
Epithelial-to-mesenchymal transition [Vella 2014; Greening et al. 2015].  
Cancer exosomes are potentially strong mediators with a natural ability for modulating the 
behavior of surrounding cells. This enables metastasis to take place by conditioning the 
environment, colonizing and facilitating cancer cells migration. In a series of experiments, 
Sung et al., found that exosome secretion was associated with directional cell movement and 
persistent migration of cancer cells[Sung et al. 2015].Using live-cell imaging Sung et al found 
that the inhibition of exosome biogenesis led to the disruption of directional cancer cell 
migration. Moreover, reactivating the biogenesis pathways led to the re-establishment of cell 
transportation and movement. Thus, cancer exosomes are capable of secreting and delivering, 
essential ECM molecules to drive the migration of cancer cells by adjusting cell adhesion with 
an effect on integrin [Peinado et al. 2012].Valenzuela et al., have reported that exosomes 
secreted from tumor cell lines contain survivin, cIAP1, cIAP2, and XIAP; which all have an 
inhibitory effect on apoptosis (IAPs) [Valenzuela et al. 2015]. 
The effects of cancer exosomes on the immune system appear to be at least two fold. They can 
promote the immune response to the tumor, or enhance immunosuppressive functions that 
support tumorigenesis.  Cancer cell-derived exosomes can induce apoptosis of CD8+ T cells 
by means of the death receptor pathway [Peng, Yan, and Keng 2011].They may also be 
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responsible for T cell dysregulation by supporting regulatory T cells proliferation while 
inhibiting the proliferation of effector T cells [Miller and Grunewald 2015]. 
Exosomes and Breast cancer: Diagnosis 
Some studies have reported that exosomes extracted from the saliva, may be used for 
diagnosing early Breast cancer [48]. Exosomes derived from breast cancer (exo-Breast cancer) 
appear to be able to interact with salivary gland cells and modify the configuration of the 
secreted exosomes by changing transcriptional activity [Zhang et al. 2016]. Furthermore, 
particular exo-Breast cancer proteins and mRNAs could be found in saliva [Zhang and Grizzle 
2014; Lau and Wong 2012]. It is possible that, controlling mRNA and protein expressions may 
be a feasible way of protecting individuals at high risk of breast cancer. Another investigation 
reported a relationship between exosomal survivin expression and breast cancer. In this study, 
patients were compared with controls that were disease free for 5 years, these patients had a 
significant increase in the serum survivin level (specifically survivin-2B). Thus, measuring 
serum survivin-B2 could be another way of monitoring the breast cancer risk [Khan et al. 
2011]. Recently, Roberg-Larsen et al. found a large population of particular extracellular 
vesicles named HG-NV (Homogenous nano vesicle/Huang-Ge-nano vesicle) in a breast cancer 
cell line [Roberg-Larsen et al. 2017]. Zhang et al. showed that some specific proteins and 
RNAs exist in breast cancer cells derived from HG-NVs. These may be used as potential 
biomarkers for breast cancer diagnosis [Zhang et al. 2016]. 
Additionally, Melo et al., reported that the cell surface proteoglycan, GPC1 (glypican-1), may 
be a specific cancer biomarker. According to the results of this study, in 75% of patients with 
breast cancer, the levels of exosomes with GPC1 on their surface (GPC1+) are higher, than for 
healthy controls [Melo et al. 2015]. 
Exosomes and Breast cancer: a potential therapeutic option 
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To date, there are four common therapeutic options for breast cancer: chemotherapy, 
radiotherapy, endocrine therapy and surgical excision; although, the results of these treatments 
is often poor, with a high risk of relapse and side effects, including venous thrombus, 
leukaemia, neurotoxicity and cardiotoxicity [Overmoyer 2015; Feng et al. 2014]. 
Immune promoting attributes of exosomes may allow them to be used as cellular vehicles as 
novel drug delivery tools, or vaccines for cancer immune therapy. These vaccines, allow the 
presentation of tumor antigens to the immune system that produces an effective immune 
responses against the tumor [Koido et al. 2011]. Because TD exosomes contain various tumor 
antigens, they may participate in antigen presentation to activate T cells such as dendritic cells 
and appear to be a feasible cancer vaccine [Cho et al. 2005; Tan, De La Peña, and Seifalian 
2010]. Many nano carriers have been developed into drug delivery systems, because of the ease 
of application, little likelihood of toxicity and sustained effect, because of their lack of 
elimination by the reticuloendothelial system. As natural carriers, exosomes are safe and 
effective for targeted tumor drug delivery or therapy [Tian et al. 2014]. Ohno et al., have 
reported that exosomes can effectively deliver let-7a to breast cancer cells with epidermal 
growth factor receptors; GE11 peptide that binds to epidermal growth factor receptor-positive 
exosomes are an appropriate vehicle for delivering drugs to tumors’ that express epidermal 
growth factor receptor [Ohno et al. 2013]. 
 
 
Conclusion 
Exosomes are the very small EVs that appear to have important roles in the progression and 
metastasis of cancer. By transporting specific contents such as lipids, proteins, and transferring 
RNA, they may be able to mediate intercellular communication in TME. There is growing 
evidence that exosomes can be utilized as biomarkers for breast cancer. Furthermore, exosomes 
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have the potential to be potent drug transporters, allowing the targeted delivery of therapeutic 
agents to the sites of tumor cells. Whilst, further work is needed, exosomes, could be used as a 
non-invasive and effective mechanism to fight cancer in the future.  
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